Eyal Meiri
Experienced in DICER1 Syndrome

Dr. Eyal Meiri

Oncology | Hematology
Piedmont Healthcare
Piedmont Physicians Medical Oncology Atlanta
1800 Howell Mill Road Suite 300, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in DICER1 Syndrome
Piedmont Healthcare
Piedmont Physicians Medical Oncology Atlanta
1800 Howell Mill Road Suite 300, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Eyal Meiri earned his medical degree from University of Toronto and completed his residency at Sinai Hospital of Detroit. He is fellowship-trained in oncology and hematology and is board certified in Internal Medicine and Medical Oncology. Prior to joining Piedmont, he was the Chief of Medical Oncology at Cancer Treatment Centers of America. Dr. Meiri has been practicing medicine for over 33 years and specializes in GI Cancers and Neuroendocrine Tumors.

In his spare time, Dr. Meiri enjoys spending time reading, listening to audio books and podcasts, traveling, the Toronto Maple Leafs, and live concerts.

Dr. Meiri is accepting new patients and welcomes most major insurance plans.

Dr. Meiri is rated as an Experienced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Toronto Faculty Of Medicine (Canada), 1983
Residency
Sinai Grace Hospital, Internal Medicine, 1986
Specialties
Oncology
Hematology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine - Medical Oncology
Fellowships
Henry Ford Hospital, Medical Oncology, 1988
Hospital Affiliations
Piedmont Hospital, Inc
Piedmont Henry Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Piedmont Physicians Medical Oncology Atlanta
1800 Howell Mill Road Suite 300, Atlanta, GA 30318
Call: 404-425-1777

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Enrollment Status: Recruiting
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drugs: Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Trastuzumab and Pertuzumab, Vemurafenib and Cobimetinib, Regorafenib, Olaparib, Pembrolizumab, Nivolumab and Ipilimumab, Abemaciclib, Afatinib, Talazoparib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Entrectinib, Larotrectinib, Tucatinib plus Trastuzumab Subcutaneous (SC)
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

1 Total Publications

A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Journal: Journal of cardiovascular pharmacology
Published: February 23, 2013
Similar Doctors
Leda P. Gattoc
Advanced in DICER1 Syndrome
Dr. Leda P. Gattoc
Oncology
Advanced in DICER1 Syndrome
Dr. Leda P. Gattoc
Oncology

Piedmont Physicians Gynecologic Oncology Atlanta

1800 Howell Mill Rd, Ste 300, 
Atlanta, GA 
 (1.2 miles away)
404-425-1380
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Leda Gattoc is a Gynecologic Oncologist at Piedmont Healthcare. She earned her medical degree at New York University in New York City and completed her residency in Obstetrics and Gynecology at Long Island Jewish Hospital in New Hyde Park, NY. After residency, she completed a Pelvic Surgery Fellowship at Emory University where she also obtained her degree in Master of Science in Clinical Research. Dr. Gattoc then went on to complete her fellowship in Gynecologic Oncology at Wayne StateUniversity/ Karmanos Cancer Institute in Detroit, Michigan.Dr. Gattoc is board certified in both Gynecologic Oncology and Obstetrics and Gynecology. She also has a designated practitioner certification in Minimally Invasive Gynecologic Surgery. She is a member of the Society of Gynecologic Oncology, American College of Obstetricians & Gynecologists and American Association of Gynecologic Laparoscopists. Dr. Gattoc is dedicated to providing high quality, personalized care to women with gynecologic cancers utilizing both surgery and chemotherapy. She has a special interest in pre-invasive diseases, minimally invasive robotic and laparoscopic surgeries and complex benign gynecologic conditions. She is fluent in English, Spanish and Tagalog. Dr. Gattoc is accepting new patients and welcomes most major insurance plans. Dr. Gattoc is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Lump in the Abdomen, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Endometrial Stromal Sarcoma, and Hysterectomy.

Benjamin R. Wilson
Advanced in DICER1 Syndrome
Dr. Benjamin R. Wilson
Oncology
Advanced in DICER1 Syndrome
Dr. Benjamin R. Wilson
Oncology

Piedmont Physicians Gynecologic Oncology Athens

1010 Prince Ave, Suite 300, 
Athens, GA 
 (58.4 miles away)
706-425-1470
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ben Wilson, MD specializes in Gynecologic Oncology. He is board eligible for Obstetrics and Gynecology and Gynecologic Oncology.Prior to joining Piedmont, he completed his fellowship, dedicating a year of research to drug discovery for Ovarian Cancer and two clinical years of training with an emphasis in robotic surgery. He uses advanced surgical techniques and chemotherapy to treat gynecologic malignancies such as ovarian, uterine, cervix, and vulvar cancer and complex gynecologic conditions. Dr. Wilson is rated as an Advanced provider by MediFind in the treatment of DICER1 Syndrome. His top areas of expertise are Lump in the Abdomen, Angiomyoma, Uterine Fibroids, Endometritis, and Osteotomy.

Mitzie-ann Davis
Advanced in DICER1 Syndrome
Dr. Mitzie-ann Davis
Oncology
Advanced in DICER1 Syndrome
Dr. Mitzie-ann Davis
Oncology

Piedmont Physicians Breast Surgery And Gynecologic Oncology Fayetteville

1279 Highway 54 West, Suite 100, 
Fayetteville, GA 
 (22.5 miles away)
770-719-5710
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mitzie-Ann Davis, M.D. earned her undergraduate degree from Swarthmore College in Swarthmore, Pennsylvania and her medical degree from the Temple University School of Medicine in Philadelphia, Pennsylvania. She completed her residency in obstetrics and gynecology at Pennsylvania Hospital in Philadelphia and then went on to receive her Master of Public Health from Johns Hopkins University. Prior to joining Piedmont Physicians, Dr. Davis completed fellowship training in gynecologic oncology at the University of California San Diego. Dr. Davis is a Fellow of the American College of Obstetricians and Gynecologists and is a member of the Society of Gynecologic Oncologists, American Medical Association and the Sigma Xi Research Society. She is fluent in Spanish and in her spare time, enjoys cooking and traveling. Dr. Davis is rated as a Distinguished provider by MediFind in the treatment of DICER1 Syndrome. Her top areas of expertise are Lump in the Abdomen, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Endometrial Stromal Sarcoma.

VIEW MORE DICER1 SYNDROME DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meiri's expertise for a condition
ConditionClose
    • Distinguished
    • Colorectal Cancer
      Dr. Meiri is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Meiri is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Meiri is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Neuroendocrine Tumor
      Dr. Meiri is
      Distinguished
      . Learn about Neuroendocrine Tumor.
      See more Neuroendocrine Tumor experts
    • Pancreatic Cancer
      Dr. Meiri is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Advanced
    • Ampullary Cancer
      Dr. Meiri is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Meiri is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
      Dr. Meiri is
      Advanced
      . Learn about Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
      See more Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) experts
    • Gastroesophageal Junction Cancer
      Dr. Meiri is
      Advanced
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Gastrointestinal Stromal Tumor
      Dr. Meiri is
      Advanced
      . Learn about Gastrointestinal Stromal Tumor.
      See more Gastrointestinal Stromal Tumor experts
    • Lynch Syndrome
      Dr. Meiri is
      Advanced
      . Learn about Lynch Syndrome.
      See more Lynch Syndrome experts
    View All 11 Advanced Conditions
    • Experienced
    • Adrenocortical Carcinoma
      Dr. Meiri is
      Experienced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Meiri is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Meiri is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Meiri is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alveolar Soft Part Sarcoma
      Dr. Meiri is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Anal Cancer
      Dr. Meiri is
      Experienced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.